Understand the source comparison
Peptides Help With Rotator Cuff Injuries: Research Peptides Comparison
Different peptides target different stages of the rotator cuff healing cascade. This table compares the three most-researched compounds based on mechanism, evidence quality, and practical administration considerations. BPC-157 VEGF upregulation, nitric oxide p
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Different peptides target different stages of the rotator cuff healing cascade. This table compares the three most-researched compounds based on mechanism, evidence quality, and practical administration considerations.
- BPC-157
- VEGF upregulation, nitric oxide pathway activation, fibroblast migration enhancement
- Moderate—multiple animal studies, no human RCTs
- 200–500 mcg/day subcutaneous
- Local injection near injury site or systemic subcutaneous
- Strongest preclinical evidence for direct tendon repair—mechanism aligns well with rotator cuff pathology
- TB-500 (Thymosin Beta-4)
- Actin-binding protein, promotes cell migration, reduces inflammation
- Low—in vitro studies and animal models, no controlled human trials
- 2–5 mg twice weekly
- Subcutaneous or intramuscular
- Plausible mechanism for early-stage healing, but human evidence gap is significant
- MK-677 (Ibutamoren)
- Growth hormone secretagogue, elevates IGF-1 systemically
- Moderate—human trials exist for GH elevation, indirect tissue repair evidence
- 10–25 mg/day oral
- Oral administration
- Indirect support through systemic anabolic environment—less targeted than BPC-157 but easier administration
- IGF-1 LR3
- Direct IGF-1 receptor agonist, protein synthesis stimulation
- Low—limited published research, mostly bodybuilding anecdotal use
- 40–80 mcg/day
- Subcutaneous
- Potent anabolic signal but lacks tissue-specific targeting—risk of off-target effects
- BPC-157 stands out because its mechanism directly addresses the vascular limitation in rotator cuff tendons—improved blood flow means better nutrient delivery to an already poorly vascularised structure. TB-500's migration-enhancing properties theoretically benefit early inflammation phases, but the absence of human data makes dosing protocols speculative. MK-677 offers the advantage of oral bioavailability and established human safety data, though its effects are generalised rather than injury-specific.